Starting Lantus in an Insulin-Naïve Type 2 Diabetic with A1C 10.8%
Start Lantus at 10 units subcutaneously once daily at the same time each day (bedtime is preferred), and continue the glipizide 5 mg daily. 1
Initial Dosing Strategy
Given this patient's A1C of 10.8% (which exceeds 10%), the 2025 ADA guidelines specifically note that insulin should be considered as the first injectable therapy when A1C levels are very high (>10%) 2. However, since this patient is already on glipizide, you're appropriately adding basal insulin rather than starting from scratch.
The FDA-approved starting dose for insulin-naïve type 2 diabetics is:
- 10 units once daily (or 0.2 units/kg if weight-based dosing is preferred) 1
- Administer at the same time every day
- Continue the glipizide initially—do not discontinue it 1
Titration Protocol
After initiating at 10 units, use a structured titration algorithm to reach target fasting blood glucose <100 mg/dL (5.5 mmol/L):
Patient-managed titration (more aggressive, faster A1C reduction):
- Increase by 2 units every 3 days if fasting glucose remains elevated and no hypoglycemia (glucose <72 mg/dL) occurs 3
- This approach achieved greater A1C reduction (-1.22% vs -1.08%) in the AT.LANTUS trial 3
Clinic-managed titration (lower hypoglycemia risk):
- Adjust dose every 3-7 days based on mean fasting glucose over previous 3 days 3:
- If FBG ≥180 mg/dL: increase by 6-8 units
- If FBG 140-179 mg/dL: increase by 4 units
- If FBG 120-139 mg/dL: increase by 2 units
- If FBG 100-119 mg/dL: increase by 0-2 units
- If FBG <100 mg/dL: no change (at goal)
Critical Safety Considerations
Hypoglycemia monitoring is essential:
- The combination of glipizide (a sulfonylurea) plus insulin increases hypoglycemia risk 1
- If hypoglycemia occurs without clear cause, reduce the corresponding insulin dose by 10-20% 2
- Consider reducing or discontinuing glipizide if recurrent hypoglycemia develops, particularly as insulin doses escalate
Important administration details:
- Never mix Lantus with other insulins or solutions 1
- Rotate injection sites within the same region (abdomen, thigh, or deltoid) 1
- Do not administer intravenously or via insulin pump 1
Expected Outcomes and Next Steps
With an A1C of 10.8%, expect approximately 1.3-1.5% A1C reduction with basal insulin alone 4. This patient will likely need 30-50 units daily by the time titration is complete to reach goal, though individual requirements vary significantly.
If A1C remains >7% after 3 months on optimized basal insulin:
- Consider adding a GLP-1 receptor agonist before adding prandial insulin 2
- If GLP-1 RA is not an option and A1C remains elevated, add one dose of rapid-acting insulin with the largest meal (typically 4 units or 10% of basal dose) 2
The key pitfall to avoid is therapeutic inertia—this patient needs aggressive titration given the markedly elevated A1C, but must be balanced against hypoglycemia risk from the concurrent sulfonylurea.